Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Carcinoma, Renal Cell 23Glioblastoma 13Lymphoma, Mantle-Cell 10Endometrial Neoplasms 10Prostatic Neoplasms 9Neoplasms 9Breast Neoplasms 9Brain Neoplasms 9Neoplasm Metastasis 8Kidney Neoplasms 8Gliosarcoma 8Melanoma 7Sarcoma 6Lymphoma, Non-Hodgkin 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Ovarian Neoplasms 5Oligodendroglioma 5Multiple Myeloma 5Lymphoma, Follicular 5Lymphoma 5Glioma 5Astrocytoma 5Waldenstrom Macroglobulinemia 4Uterine Cervical Neoplasms 4Lymphoma, B-Cell, Marginal Zone 4Fallopian Tube Neoplasms 4Central Nervous System Neoplasms 4Unspecified Adult Solid Tumor, Protocol Specific 3Rhabdomyosarcoma 3Osteosarcoma 3

Interventions

temsirolimus 2liposomal doxorubicin 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Resistant Solid Malignancies × temsirolimus × Clear all
NCT00703625 2017-03-07

Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies

Washington University School of Medicine

Phase 1 Completed
26 enrolled

Resistant Solid Malignancies

NCT00703170 2013-05-24

Phase I Study of DOXIL and Temsirolimus in Resistant Solid Malignancies

Washington University School of Medicine

Phase 1 Completed
28 enrolled

Resistant Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡